Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
• Burlington Stores (BURL) PT Raised to $440 at UBS